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To compare the effectiveness of cromolyn sodium (CS)
(10 mg) and nedocromil sodium (NS) (4 mg) adminis-
tered by a metered dose inhaler (MDI) with a spacer
device in preventing exercise-induced asthma (EIA), eight
asthmatic children with EIA were studied in a
randomized double-blind, cross-over, placebo-controlled
study, cs and NS provided significant, comparable pro-
tection from EIA and both were better than placebo. We
conclude that CS and NS administered by a pressurized
aerosol with a spacer device provide equal protection
against EIA in children.
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Introduction
Cromolyn sodium (CS) and nedocromil sodium
(NS) are two anti-inflammatory drugs which have
been shown to be effective in preventing exercise-
induced asthma (EIA) in both adults and children. 1-4
Metered dose inhalers provide an aerosolized dose
with high particle velocity, necessitating respiratory
coordination to obtain optimal drug deposition in
the lung. The use of a spacer device attached to the
MDI reduces the velocity of aerosol particles and
significantly improves drug delivery to the peripheral
lung. To compare the effectiveness of CS and NS
administered by a MDI with a spacer device in
preventing EIA in childhood, a double-blind, cross-
over, placebo-controlled study was performed.
Subjects and Methods
The study was double-blind, randomized, cross-
over and placebo-controlled. Eight patients (five
males, three females), aged 7 to 11 years (mean 8.7
+ 11.2 years) were recruited. All patients attended the
Pediatric Asthma Clinic at Perugia General Hospital,
and all had asthma as defined by the American
Thoracic Society. All subjects previously demon-
strated a consistent fall in FEV of at least 15% from
baseline after a 6 min standard treadmill exercise
screening test. They were being treated with different
anti-asthmatic regimens, such as sustained release
theophylline, beta-agonists, SCG, NCS, and inhaled
steroids; none was under therapy with oral steroids.
Sustained release theophylline was withheld for 24 h,
and other drugs for 12 h before each exercise test.
None of the subjects had had respiratory infections
in the 4 weeks before the trial. Informed consent was
obtained from patients and their parents, and the
protocol was approved by the Hospital Ethics Com-
mittee.
The screening test consisted of steady state run-
ning for 6 min on a treadmill at an incline which
would produce a heart rate of at least 85% of the
maximum predicted for age. After screening in
randomized order on 3 separate days, patients
were tested on different treatments inhaled from a
metered dose inhaler with a spacer device
(Aerochamber, Trudell Medical, London, Ontario):
SCG (5 mg twice), or NCS (2 mg twice), or placebo
(2 puffs). The drugs were administered by a trained
physician, and all the patients were skilled in the use
of MDI with aerochamber. The patients performed
the exercise test 20 min after every drug inhalation.
Each patient always performed tests at the same time
of the day, and all four tests were completed within
10 days.
Room temperature and relative humidity were
monitored. Differences of IC in temperature and 5
mg H,.O/1 of air in water content on the test days of
each patient were considered acceptable.
8 Room
temperatures ranged from 21 to 23C, and relative
humidity from 48% to 58% on the different study
days.
Pulmonary function was measured by a turbin
spirometer (Pocket Spirometer I: Micro Medical
Limited, Rochester, Kent, UK), according to accepted
standards.9,1 Predicted normal values for spirometry
were obtained from the study of Knudson et al.1 All
children were already familiar with the spirometer.
Measurements were performed before drug inhala-
tion (baseline value), before every exercise test (pre-
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exercise value), and then 3, 5, 10, 15 and 30 min after
the end of exercise. Heart rate was also measured
before and immediately after the exercise. The exer-
cise test was performed only if the baseline FEV1 was
greater than 70% of the mean predicted for the child’s
height, and if the baseline FEV varied < 10% from
the values on previous test days. The following
indices were calculated from the results of the pul-
monary function tests:
(A) Maximum % fall FEV1
pre-exercise FEV lowest FEV post-exercise
pre-exercise FEV
(B) % protection FEV1-
Ps Pt
Ps
where Ps is the percentage fall FEV at the screening
test, and Pt is the percentage fall FEV after each
treatment.
Complete protection was considered to have been
obtained if the percentage fall in FEV1 was within the
normal range (< 100). 12 Clinical protection was con-
sidered to have been obtained if the percentage fall
after receiving the active drug was half or less of the
percentage fall after receiving placebo.
Analysis of data: Analysis of variance for repeated
measures and Student’s t-test for paired data, includ-
ing the Bonferroni adjustment, were used. Differ-
ences were considered significant ifp < 0.05.
Results
Mean pre-drug baseline FEV1 values on different
study days were statistically comparable (CS: 1.60 L;
NS: 1.62 L; PL: 1.57 L), and no change of mean FEV
was observed 20 min after administration of each one
of three formulations (CS. 1.58 L; NS. 1.63 L; PL: 1.61
L). No statistically significant differences emerged in
pre-exercise values in the three groups.
The mean maximum percentage fall in FEV
(+ S.D.) in the screening test, after placebo, CS and
NS was 38.8 + 11.2, 31.4 + 20.6, 14.8 + 18.6 and 13.3
+ 8.1. A significant decrease in mean percentage fall
in FEV with respect to baseline exercise test was
observed after treatment with CS and NS, but not
with placebo. Student t-test baseline versus. (A) Pla-
cebo: p not significant; (B) CS.p < 0.005; (C) NS.
p < 0.005. The decrease of percentage fall FEV ob-
tained with CS and NS was comparable (Student t-
test:p not significant), and both drugs were signifi-
cantly better than placebo (p < 0.005). It was found
that 5/8 (62.5%), 4/8 (50%) and 1/8 (12.5%) subjects
were completely protected by CS, NS and placebo,
respectively. Only 4/8 (50%) patients received com-
plete protection from both active drugs (Table 1).
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Table 1. Maximum percentage fall in FEV after exercise
Patient n Screening Placebo CS NS
40.2 22.1 20.1 6.3
2 61.4 35.3 15.9 32.7
3 28.0 1.3 10.0 0.6
4 36.0 18.0 9.9 5.6
5 45.3 52.9 16.9 17.1
6 38.6 67.4 28.6 52.3
7 36.8 24.7 0.0 0.0
8 24.8 29.5 5.1 3.8
Mean 38.8 31.4 13.3 14.8
SD 11.2 20.6 8.9 18.6
Table 2. Percentage of protection from EIA
Patient n Placebo CS NS
45 84 50
2 42 47 74
3 95 98 64
4 49 84 72
5 0 62 62
6 0 0 26
7 32 100 100
8 0 85 79
Mean 32.8 13.3 14.8
SD 32.9 8.9 18.6
The protection percentage was 70.0 + 33.3, 65.8 +
21.7 and 32.8 + 32.9 for CS, NS and placebo, respec-
tively. A protection value greater than 50% (clinical
protection) was obtained in 6/8 (75%) patients
treated with SC, 7/8 (87.5%) treated with NS, and
1/8 (12.5%) patients who received placebo
(Table 2).
Discussion
Both CS and NS have been shown to be effective
in protecting against EIA in children. 3,4 The mecha-
nism by which these two drugs exert their action in
preventing EIA has yet to be determined, but both
drugs exhibit a considerable protective effect on the
mucosal mast cells in vivo and in vitro. 1,14
This double-blind, within patient comparative
study shows that CS and NS inhaled by a MDI with
a spacer device have a significant and comparable
effect in preventing EIA in children, and that both
drugs are more effective than placebo.
Our data are in agreement with those from other
studies, which showed the comparable effectiveness
of CS and NS in preventing EIA, both in adults15a6 and
in children. 17,18 A variable protective effect, which is
highlighted by the large standard deviation of the
mean maximum fall in FEV1, was found between CS
and NS in some of our patients. This has beenExercise-induced asthma
previously reported in other studies16,19 and may
reflect the response variability that exists between
asthmatics. 15
Patel and Albazzaz19 found a significantly higher
protection against EIA with NS when compared with
CS. In addition, Morton et al. 15 reported that the
percentage of adults who were completely protected
from EIA was higher after NS (62.5%) than after CS
(25%). However, as CS was administered at a low
dosage, the results may have been distorted.
The use of a spacer device in adjunct to MDI
has been strongly advocated for children who
may not be able to perform the inhalation
correctly. However, although spacer devices
have several potential advantages over MDIs,
their use did not modify the effect of both CS and
NS in a previous study. 17 This was probably due to
the correct technique by which previously skilled
children used MDI, allowing optimal drug deposition
to peripheral airways.
A statistically significant effect of a drug on EIA
does not necessarily indicate the effect is clinically
important. Therefore, we also evaluated the protec-
tion percentage against EIA, as an index of a good
clinical control. This analysis yielded the same results
as the analysis of the percentage fall FEV1 itself.
It is concluded that CS and NS provide equal
protection against EIA in children when the clinical
recommended dose is administered by a pressurized
aerosol with an aerochamber. Further studies are
needed to compare the duration of action of these
two drugs in inhibiting EIA.
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